Related Experiment Video

Updated: Aug 24, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
14:18

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Pediatric IgA nephropathies: clinical aspects and therapeutic approaches

Noel M Delos Santos1, Robert J Wyatt

  • 1Children's Foundation Research Center at the Le Bonheur Children's Medical Center and the Department of Pediatrics, University of Tennessee Health Sciences Center, Memphis, TN, USA.

Seminars in Nephrology
|May 25, 2004
PubMed

Insights

Pediatric IgA nephropathies, including Berger's Disease and Henoch-Schönlein purpura nephritis, show variable severity. Limited evidence from clinical trials hinders strong treatment recommendations for these kidney diseases.

Area of Science:

  • Nephrology
  • Pediatric Nephrology
  • Immunology

Background:

  • IgA nephropathies encompass Berger's Disease and Henoch-Schönlein purpura nephritis in children.
  • These conditions represent significant causes of kidney disease in pediatric populations.

Purpose of the Study:

  • To review the epidemiology, clinical features, outcomes, prognostic markers, and therapeutic strategies for pediatric IgA nephropathies.
  • To highlight the challenges in establishing definitive treatment guidelines due to variable disease presentation and limited clinical trial data.

Main Methods:

  • Comprehensive literature review of IgA nephropathies in pediatric patients.
  • Analysis of existing data on disease characteristics, prognosis, and treatment efficacy.

Main Results:

  • Both Berger's Disease and Henoch-Schönlein purpura nephritis exhibit considerable variability in disease severity and patient outcomes.
  • Current therapeutic approaches lack robust evidence from randomized clinical trials to support definitive treatment recommendations.

Conclusions:

  • Effective management of pediatric IgA nephropathies is challenged by heterogeneity in disease presentation and outcome.
  • Further high-quality research, particularly randomized clinical trials, is needed to guide therapeutic interventions for these kidney disorders.

More Related Videos

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...